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SUMMARY
Increased expression of the transcription/translation regulatory protein Y-box binding protein-1 (YB-1) is
associated with cancer aggressiveness, particularly in breast carcinoma. Here we establish that YB-1 levels
are elevated in invasive breast cancer cells and correlate with reduced expression of E-cadherin and poor
patient survival. Enforced expression of YB-1 in noninvasive breast epithelial cells induced an epithelial-
mesenchymal transition (EMT) accompanied by enhanced metastatic potential and reduced proliferation
rates. YB-1 directly activates cap-independent translation of messenger RNAs encoding Snail1 and other
transcription factors implicated in downregulation of epithelial and growth-related genes and activation of
mesenchymal genes. Hence, translational regulation by YB-1 is a restriction point enabling coordinated
expression of a network of EMT-inducing transcription factors, likely acting together to promote metastatic
spread.INTRODUCTION
Mammalian Y-box binding protein-1 (YB-1) is a member of the
DNA/RNA-binding family of proteins with an evolutionarily
conserved cold-shock domain (CSD). Both bacterial and
mammalian cold-shock domain proteins are ubiquitously ex-
pressed and involved in fundamental processes such as DNA
repair, mRNA transcription, splicing, translation, and stabiliza-
tion (Evdokimova and Ovchinnikov, 1999; Kohno et al., 2003).
Consistent with its essential biological functions, targeted
disruption of YB-1 in mice causes severe developmental defects
and embryonic lethality (Lu et al., 2005).402 Cancer Cell 15, 402–415, May 5, 2009 ª2009 Elsevier Inc.Numerous studies point to a role for YB-1 in malignant transfor-
mation, with evidence for both oncogenic and tumor-suppressive
functions. A prooncogenic role for YB-1 is suggested by its higher
expression in actively proliferating tissues and multiple human
malignancies, as well its ability to activate transcription of prolif-
eration-related genes through binding to the Y-box promoter
elements of the latter (Kohno et al., 2003). However, only a few
reports have directly addressed the biological role of YB-1 in
tumorigenesis. Bergmann et al. (2005) found that elevated YB-1
expression in mammary glands caused chromosomal instability
and induced invasive breast carcinomas in lactating transgenic
mice. Another study demonstrated that in vitro YB-1SIGNIFICANCE
Dissemination of malignant cells during breast cancer progression is hypothesized to occur through the acquisition of
a migratory mesenchymal-like phenotype. Such cells may then remain quiescent only to resume their growth after years
of dormancy. We demonstrate that increased YB-1 expression combined with sustained Ras-ERK activation induces
epithelial dedifferentiation andmetastatic ability, while simultaneously inhibiting tumor growth. YB-1-overexpressing breast
cancer cells therefore closely recapitulate the early steps of metastatic spread and acquired dormancy and are likely to be
insensitive to conventional therapies directed at eradicating dividing cells. Our findings argue against direct targeting of
YB-1 as this may reactivate proliferation of dormant metastatic cells. Instead, we propose that inactivating potential down-
stream effectors of YB-1 may be a better therapeutic strategy.
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YB-1-Mediated Translational Control of EMToverexpression in MCF-7 breast carcinoma cells enhances their
proliferation and soft agar colony formation (Sutherland et al.,
2005). These protumorigenic activities are proposed to involve
nuclear localization and transcriptional activation by YB-1.
In contrast, cytosolic YB-1 exhibits potent tumor-suppressive
activity (Bader and Vogt, 2007). In normal mouse and human
tissues as well as in cultured cells, YB-1 predominantly localizes
to the cytoplasm where it is found in complexes with translation-
ally inactive mRNAs (Evdokimova and Ovchinnikov, 1999). This
has led to the notion that the tumor suppressor function of YB-1
involves translational silencing of progrowth transcripts, which
are less competitive in translation initiation due to their extended,
highly structured 50UTRs (Bader and Vogt, 2005; Evdokimova
et al., 2006a). Using a microarray approach, we previously iden-
tified diverse growth-related mRNAs that were silenced through
specific binding to YB-1 in K-Ras-transformed NIH 3T3 cells
(Evdokimova et al., 2006b). Translational silencing by YB-1 may
arise from its ability to bind in close proximity to the 50 mRNA
cap structure and displace the eIF4E-driven translation initiation
complex from mRNAs (Bader and Vogt, 2005; Evdokimova et al.,
2006b, 2001). YB-1’s ability to repress cap-dependent transla-
tion and tumor growth can be disabled by AKT-mediated
phosphorylation (Bader and Vogt, 2007; Evdokimova et al.,
2006b). Thus elevated PI3K-AKT signaling is predicted to reverse
the inhibitory effects of YB-1. Moreover, AKT activation may
induce the progrowth activities of YB-1 by triggering its nuclear
translocation (Sutherland et al., 2005). Binding of key growth-
related mRNAs in the cytoplasm by YB-1 may protect these
transcripts from degradation under conditions unfavorable for
proliferation, allowing for their rapid deployment through transla-
tion in response to proliferative stimuli without the need for
transcriptional activation (Evdokimova et al., 2006a). In this study
we investigated the effects of YB-1 on breast cancer progression
to further explore the role of cytosolic YB-1 in oncogenesis.
RESULTS
YB-1 Promotes an Epithelial-Mesenchymal Transition
andReduces Proliferation ofMCF10ATBreast Epithelial
Cells
To address the potential contribution of YB-1 to breast tumori-
genesis, HA-tagged YB-1 was ectopically expressed in immor-
talized benign MCF10A human mammary epithelial cells or their
premalignant MCF10AT subclone. The latter is derived by trans-
formation with oncogenic H-Ras and subsequent passaging
through mouse xenografts. This model closely recapitulates
the histological characteristics of mammary hyperproliferative
disease and its ability to progress to carcinoma in situ and inva-
sive cancers (Dawson et al., 1996). Parental MCF10A cells
exhibit a cuboidal, cobblestone morphology in monolayer
cultures, with tight cell-cell contacts characteristic of normal
mammary epithelial cells (Debnath et al., 2003). This morphology
was observed for both vector alone (MCF10A and MCF10AT)
and MCF10A-YB-1 cell lines (Figure 1A, top row). Surprisingly,
however, ectopic expression of YB-1 in MCF10AT cells at levels
that are 2-fold higher than endogenous YB-1 (see Figure 1B)
led to loss of cell-cell contacts and the emergence of
a spindle-shaped, fibroblast-like morphology. MCF10AT-YB-1
cells formed cord-like networks of cells with extremely longmembrane extensions resembling filopodia. This was accompa-
nied by virtually complete loss of epithelial E-cadherin and the
tight junction protein ZO-1, and reduced expression of other
epithelial markers including cytokeratin 18 (CK18) and mucin 1
(MUC1) (Figures 1A and 1B and Figure S1A available online).
Instead, these cells expressed mesenchymal N-cadherin and
many proteins characteristic of basal/myoepithelial or even
progenitor-like cell lineages, such as fibronectin, vimentin,
a-smooth muscle actin (SMA), CK14, and p63 (Figures 1B and
Figure S1A). These alterations are characteristic of cells that
have undergone an epithelial-mesenchymal transition (EMT),
a process whereby epithelial cells lose polarity, cell-cell
contacts, and cytoskeletal integrity and acquire metastatic
ability (Thiery and Sleeman, 2006). Similar results were obtained
in YB-1-overexpressing H-Ras-transformed EpH4 mouse
mammary epithelial cells as well as in cervical and prostate
carcinoma cells (Figures S1B–S1E), indicating that elevation of
YB-1 levels may enhance mesenchymal properties in a broad
range of human carcinomas.
In addition, MCF10AT-YB-1 cells exhibit reduced expression
of certain G1/S and mitotic cyclins (cyclins A2, B1, D1, D3, and
E1; Figure 1C) and significantly lower proliferation rates
(Figure 1D). In contrast to MCF10AT-MSCV cells, which prolifer-
ated and maintained high expression levels of cyclins even under
serum starvation, MCF10AT-YB-1 cells failed to reenter S phase
after serum starvation (Figures 1C and 1E). Therefore, YB-1 limits
the ability of MCF10AT cells to proliferate, especially under
conditions where nutrients and growth factors are limited.
YB-1 Disrupts Mammary Acinar Architecture
and Enhances Migration of MCF10AT Cells
To gain further insights into the potential role of YB-1 in malignant
progression, we analyzed the effects of ectopic YB-1 expression
on mammary acinar morphogenesis. MCF10A cells cultured on
reconstituted laminin-rich 3D basement membranes (Matrigel)
are known to form growth-arrested acinar-like spheroids
comprised of a single layer of polarized epithelial cells
surrounding a hollow lumen. These structures closely recapitu-
late the architecture of normal mammary glands (Debnath and
Brugge, 2005; Nelson and Bissell, 2005). As expected, both
MCF10A-MSCV and MCF10A-YB-1 cells formed acinar struc-
tures with hollow lumens that reached maximal size by day 5 in
culture, whereas MCF10AT-MSCV cells formed somewhat
larger acini with filled lumens (Figure 2A and data not shown).
In striking contrast, MCF10AT-YB-1 cells were organized into
networks of loosely bound spindle-shaped cells that formed
elongated invasively growing cords (Figure 2A). These cord-
like slow-growing structures were evident by day 1 and
continued to expand until day 10, despite a lower percentage
of mitotic cells and reduced expression of cyclins D1 and D3
(Figures 2A and 3C). Examination of epithelial and mesenchymal
markers in 3D cultures by confocal microscopy confirmed that,
similar to monolayer cultures, MCF10AT-YB-1 cells expressed
exclusively N-cadherin, in contrast to the other cell lines positive
for E-cadherin (Figure 2B). Notably, HA-tagged as well as
endogenous YB-1 proteins were detected predominantly in the
cytosol (Figure 2B and Figure S2A), consistent with our hypoth-
esis that YB-1-mediated effects are mainly due to its cyto-
plasmic activities. Further support for this was obtained byCancer Cell 15, 402–415, May 5, 2009 ª2009 Elsevier Inc. 403
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YB-1-Mediated Translational Control of EMTFigure 1. YB-1 Induces EMT and Reduces Proliferation of MCF10AT Cells
(A and B) MCF10A and MCF10AT cells expressing empty vector (MSCV) or HA-YB-1 were examined by phase contrast and immunofluorescence staining (A) or
immunoblotting (B) for the expression of epithelial and mesenchymal markers. Scale bars, 100 mm.
(C) Expression patterns of cell-cycle-associated molecules in MCF10A and MCF10AT cell lines. Exponentially growing cells were either left untreated (ctrl) or
serum starved for 24 hr () and then restimulated with complete medium for the times indicated. Response to serum was confirmed by Ser-473 phosphorylation
of AKT.
(D) Growth curves of MCF10A and MCF10AT cell lines. Each data point represents the mean ± SD from three independent experiments in triplicate.
(E) Cell-cycle reentry of MCF10AT cells after serum starvation. Cells were serum starved for 24 hr and either left untreated () or restimulated with complete
medium for 2 hr (+) and labeled with BrdU to visualize cells entering S phase. Percentage of BrdU-positive cells (green) was calculated relative to total cell
populations (blue) in five random fields of view. Representative fields are shown. Scale bars, 100 mm. Averaged values from two independent experiments ±
SD are indicated.analyzing the effects of mutant YB-1 proteins on the phenotype
of MCF10AT cells. Similar to wild-type YB-1, the YB-1 Ser102-
to-Ala mutant protein, which cannot be phosphorylated by
AKT and remains cytosolic (Bader and Vogt, 2007; Evdokimova
et al., 2006b), still induced an EMT, while a truncated form of YB-
1 (1–204), which localizes exclusively to the nucleus (Sorokin
et al., 2005), did not (Figure S2B).404 Cancer Cell 15, 402–415, May 5, 2009 ª2009 Elsevier Inc.Given the mesenchymal phenotype of MCF10AT-YB-1 cells,
we hypothesized that ectopic YB-1 expression may increase
cell motility as a consequence of the EMT process. Indeed,
time-lapse imaging during wound healing revealed that
MCF10AT-YB-1 cells moved in a rapid and highly erratic fashion,
in contrast to slower-moving MCF10AT-MSCV cells, which ex-
hibited a more collective, directional migration pattern (Figures
Cancer Cell
YB-1-Mediated Translational Control of EMTFigure 2. YB-1 Disrupts Mammary Acinar Architecture and Enhances Migration
(A) MCF10A and MCF10AT cell lines were grown on Matrigel for 5 or 10 days, as indicated. Three-dimensional structures were photographed by phase-contrast
microscopy at low and high magnifications. Scale bars, 100 mm. Bottom panels depict cell-cycle distribution at day 5, as examined by FACS. Percentages of cells
in sub-G1, G1, S, and G2/M are indicated. Data shown are representative of three independent experiments.
(B) Three-dimensional structures produced by MCF10A-YB-1 and MCF10AT-YB-1 cells were examined for E-cadherin or N-cadherin expression by confocal
microscopy. Ectopic expression of HA-YB-1 and its cytosolic localization was confirmed by staining with anti-HA antibodies. Scale bars, 50 mm.
(C) Migration patterns of individual cells as determined by time-lapse imaging. The migration paths of eight cells taken from the wound edge for MCF10AT-MSCV
(top panel) and MCF10AT-YB-1 (bottom panel) cells are plotted as an x and y axis migration profile.
(D) Comparison of the average distance traveled ± SD for eight cells tracked in (C).
(E) Migration of MCF10AT cell lines toward serum or growth factors as determined by transwell migration assays. Migration toward 0.5% serum was used as
a negative control. The results of two independent experiments counted in triplicate are represented as a mean ± SD.2C and 2D and data not shown). In addition, serum-starved
MCF10AT-YB-1 cells displayed a remarkable capacity for migra-
tion in response to serum, epidermal growth factor, insulin-like
growth factor-1, or stromal-derived factor 1 (Figure 2E), suggest-
ing that they can migrate toward gradients of specific growth
factors and chemokines generated in a tumor microenviron-
ment. The difference in migration between vector alone and
YB-1-overexpressing MCF10AT cells was highest when cells
were serum starved prior to the assay (data not shown), raising
the possibility that the migratory phenotype induced by YB-1
may provide starving cells with the ability to colonize nutrient-
rich areas.YB-1 and Ras-ERK Signaling Are Both Required
for Induction of EMT
To examine if elevation of YB-1 is directly responsible for the
observed EMT in MCF10AT cells, transient transfection with
a pool of four different siRNA oligonucleotides was utilized to
specifically reduce YB-1 expression in MCF10AT-YB-1 cells.
Due to extensive protein stability, substantial reduction of YB-1
protein levels was observed only by day 4 after transfection, with
a concomitant induction of cyclins B1, D1, and D3 (but not E1
and G1) (Figure 3A). This further confirms that YB-1 is directly
responsible for blocking expression of these proteins, although
the delayed kinetics of cyclin D3 induction may indicate additionalCancer Cell 15, 402–415, May 5, 2009 ª2009 Elsevier Inc. 405
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YB-1-Mediated Translational Control of EMTregulatory mechanisms at the level of transcription or mRNA
stability. Reduced expression of YB-1 was also associated with
reexpression of E-cadherin and downregulation of N-cadherin,
vimentin, and SMA (Figure 3A and see Figures 7C and 7D), consis-
Figure 3. YB-1 and Ras-ERK Signaling Are Both Required for
Induction of EMT
(A) MCF10AT-YB-1 cells transiently transfected with 20 nM of scrambled
(siCTRL) or YB-1 (siYB-1) siRNA pools were examined for the expression of
YB-1 and potential YB-1 target proteins by immunoblotting. Cyclin G1 was
used as a loading control.
(B) MCF10A and MCF10AT cell lines were transiently transfected with 20 nM
siCTRL or siYB-1 and either left on plastic or re-plated on Matrigel 24 hr after
transfection. Morphology was examined 4 days after by phase-contrast (top
panels) or confocal (bottom) microscopy. Scale bars, 25 mM.
(C) MCF10A and MCF10AT cell lines were grown on Matrigel for 5 days and
then examined for the expression of cell cycle and signaling molecules by
immunoblotting.
(D) MCF10AT cell lines growing on Matrigel in low-serum assay medium were
treated with 50 mM PD98059, 0.1 mM wortmannin, or 20 mg/ml of pan-TGF-
b-neutralizing antibodies for 10 days. Inhibitors were added the day after
plating. Scale bars, 100 mm.406 Cancer Cell 15, 402–415, May 5, 2009 ª2009 Elsevier Inc.tent with restoration of the epithelial phenotype. When placed in
Matrigel, 30% of YB-1 siRNA-transfected MCF10AT-YB-1 cells
regained the ability to form acinar structures, whereas cells trans-
fected with control siRNA retained a fibroblastoid phenotype (Fig-
ure3B,bottom panels).Considering that the transfectionefficiency
in the MCF10AT-YB-1 cell line was 30%–50% (see Figure 7D,
middle panel), we conclude that cells lacking YB-1 regained the
ability to form acinar structures. Nevertheless, it seems likely that
YB-1 itself is not required for normal acinar morphogenesis, as
depletion of YB-1 in MCF10A cells had no effect on acinus forma-
tion (Figure 3B, top panels). The acini formed by siYB-1-treated
MCF10AT-YB-1 cells exhibited proper apicobasal polarization,
as shown by the apical orientation of the Golgi protein golgin-97
and basal deposition of the extracellular matrix protein laminin 5
(Figure 3B). However, consistent with the antiproliferative activity
of YB-1, acinar structures formed by YB-1 knockdown cells failed
to form hollow lumens and did not undergo growth arrest. After day
8 they began to revert to a more disrupted acinar architecture (data
not shown), which correlated with reexpression of YB-1 (Figure 3A,
lane 5). Therefore, in vitro acinar morphogenesis and EMT induc-
tion are inversely dependent on the expression levels of YB-1.
Next we analyzed major signaling pathways that might
contribute to the observed phenotypic changes in 3D cultures.
Not surprisingly, Ras-ERK signaling was activated in MCF10AT
cells, as evidenced by elevated levels of phosphorylated
ERK1/2 (p-ERK) and MEK (p-MEK) (Figure 3C, lane 3). For
unclear reasons, in MCF10AT-YB-1 cells, p-ERK1/2 and
p-MEK levels were even higher than in MCF10AT-MSCV cells
(Figure 3C, compare lanes 3 and 4). In contrast, PI3K-AKT and
TGF-b pathway activities were reduced in MCF10AT-YB-1 cells
based on decreased levels of p-AKT and p-SMAD proteins,
respectively (Figure 3C). To more rigorously assess if these
pathways might contribute to YB-1-associated EMT, we tested
whether the MEK inhibitor PD98059, the PI3K inhibitor wortman-
nin, or pan-TGF-b-neutralizing antibodies could influence YB-1-
mediated phenotypic changes. As shown in Figure 3D, inhibition
of Ras-ERK signaling but not TGF-b or PI3K-AKT pathways
completely abolished formation of cord-like structures in
MCF10AT-YB-1 cells, while only slightly reducing growth of
acinar structures in the other cell lines. Therefore, Ras-ERK but
not PI3K-AKT or TGF-b signaling appears to be crucial for the
observed YB-1-mediated phenotypic effects in MCF10AT cells.
These data demonstrate the necessity of both hyperactivated
Ras-ERK signaling and elevated YB-1 levels for the observed
EMT in MCF10AT cells.
Ectopic Expression of YB-1 in MCF10AT Cells Confers
Invasive and Metastatic Ability
To study the in vivo consequences of YB-1 overexpression
in premalignant breast epithelial cells, MCF10AT-MSCV or
MCF10AT-YB-1 cells were orthotopically injected into mouse
mammary fat pads. By 3 months after injection, MCF10AT-
MSCV cells were detected as multicellular E-cadherin- and cyto-
keratin-positive tumor lesions with glandular differentiation that
were strictly localized to the fat pad injection sites (Figure 4A).
In marked contrast, MCF10AT-YB-1 cells were diffusely dissem-
inated throughout the fat pads as single cells or tiny clusters. Cells
were negative for E-cadherin but positive for N-cadherin, myoe-
pithelial markers p63 and SMA, and epithelial cytokeratins
Cancer Cell
YB-1-Mediated Translational Control of EMTFigure 4. Ectopic Expression of YB-1 in MCF10AT Cells Confers Invasive and Metastatic Ability
(A and B) Hematoxylin and eosin (H&E) and immunohistochemical staining of mouse mammary fat pad sections 3 months after orthotopic transplantation of
Cherry-expressing MCF10AT-MSCV (A) or MCF10AT-YB-1 (B) cells. Arrows in (A) depict hyperplastic mCherry-positive lesions, positive for E-cadherin and
pan-CK and negative for SMA and N-cadherin. Arrowheads in (B) depict HA-YB-1-positive cells, negative for E-cadherin and Ki-67 and positive for pan-CK,
CK18, CK14, N-cadherin, p63, and SMA. Scale bars, 50 mm.
(C) Expression of HA-YB-1 mRNA was examined by semiquantitative RT-PCR in mouse tissues 3 months after orthotopic transplantation of MCF10AT-
YB-1-mCherry cells. Total RNAs isolated from MCF10AT-MSCV and MCF10AT-YB-1 cells (lanes 1 and 2) were used as negative and positive controls,
respectively. Endogenous mouse L32 mRNA levels were used as an internal loading control.(Figure 4B), consistent with these being epithelial cells having
undergone an EMT. Among the 20 mice analyzed from two inde-
pendent experiments, none of the MCF10AT-YB-1 mice devel-
oped the larger lesions localized to injection sites that were
characteristic of MCF10AT-MSCV mice, suggesting that the
observed dissemination of MCF10AT-YB-1 cells was not simply
due to differential injection of the cells within the mammary fat
pads. Their inability to grow in mouse fat pads may be explained
by their low-proliferative potential in vitro (Figures 1D and 1E) and
in vivo, based on Ki-67 staining of the fat pads (Figure 4B). Inter-
estingly, MCF10AT-YB-1 cells exhibited mixed expression of
luminal (CK18) and basal (CK14) cytokeratins, which is also
consistent with their in vitro phenotype (Figure 1B). Moreover,
these cells were also present in the thoracic cavities and lungs
of MCF10AT-YB-1 mice, as confirmed by RT-PCR detection of
HA-YB-1 transcripts (Figure 4C). Therefore, despite the failure
to develop microscopic tumor masses within the 3 month obser-
vation period, MCF10AT-YB-1 cells appear to have gained the
ability to survive and infiltrate surrounding tissue and distant
organs. These results provide strong evidence that increased
expression of YB-1 in premalignant mammary epithelial cells
with elevated Ras-ERK signaling not only blocks proliferation
but disrupts mammary morphogenesis and promotes invasive
properties and cell dissemination.
Mesenchymal-Like YB-1+E-cadherin Cells Exhibit
Invasive Behavior in Human Breast Cancers
To evaluate the potential pathophysiological relevance of our
findings, we used double immunofluorescence to comparepatterns of YB-1 expression in normal breast epithelium and
human breast carcinomas. Similar to nontransformed MCF10A
cells, YB-1 was coexpressed with E-cadherin in normal
mammary acini and localized exclusively to the cytosol of ductal
luminal cells (Figure 5A). YB-1 was absent in the outer SMA- and
p63-positive myoepithelial cell layer as well the subjacent
stroma, indicating a highly restricted pattern of expression. Like-
wise, in ductal carcinoma in situ (DCIS), a known precursor of
invasive breast cancer, neoplastic ducts were positive for both
E-cadherin and YB-1 and the surrounding myoepithelial layer
was negative for YB-1 (Figure 5B). Unexpectedly, in several
DCIS cases we noted disseminated tumor cells in subjacent
stroma that were positive for both YB-1 and SMA, but negative
for E-cadherin (Figure 5B), suggesting that EMT may be an early
event in DCIS progression. In invasive ductal carcinoma (IDC)
cases, YB-1-positive cells lacking E-cadherin could readily be
found in disseminated clusters of tumor cells penetrating into
the surrounding stroma that were clearly separate from E-cad-
herin-positive cell clusters (Figure 5C). Although these IDC cases
were classified as high-grade luminal tumors, scattered YB-1+E-
cadherin cells were also positive for SMA and occasional cells
costained for p63, thereby confirming their epithelial origin.
Coexpression of YB-1 and p63 in these cells also clearly distin-
guishes them from normal myoepithelial cells that are negative
for YB-1 (Figure 5A) and may be indicative of their progenitor-
like properties. Similar to MCF10AT-YB-1 cells in mouse studies
(Figure 4B), invasive YB-1-positive cells were low or nonprolifer-
ating, as demonstrated by their lack of staining for the prolifera-
tion markers Ki-67, PCNA, and cyclin D1 using morphometricCancer Cell 15, 402–415, May 5, 2009 ª2009 Elsevier Inc. 407
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YB-1-Mediated Translational Control of EMTFigure 5. Mesenchymal-Like YB-1+E-Cadherin Cells Exhibit Invasive Behavior in Human Breast Cancers
(A–D) Normal human breast tissues, DCIS, and IDC cases were examined for expression of endogenous YB-1, E-cadherin, SMA, p63, Ki-67, and vimentin by
immunofluorescence microscopy. Note that in normal and DCIS cases the expression of SMA and p63 was limited to myoepithelial layers negative for YB-1
and E-cadherin. Arrows depict disseminated tumor cells positive for YB-1, SMA, and p63 and negative for E-cadherin. Inset boxes show the corresponding areas
under higher magnification. Scale bars, 100 mm.analysis (Figure 5C and Figures S3A and S3B). We also analyzed
three cases of basal-like carcinoma thought to represent
a distinct subtype of IDC with properties common to breast
myoepithelial or even progenitor cells (Korsching et al., 2008)
and which are reported to express high YB-1 levels (Stratford
et al., 2007). Similar to invasive areas in other forms of IDC, there
was a reverse correlation between YB-1 and E-cadherin levels,
and some areas of basal-like tumors were positive for YB-1
and vimentin (Figure 5D). However, only occasional cells were
positive for both YB-1 and p63, and none for YB-1 and SMA
(Figures 5D and data not shown), suggesting that coexpression
of YB-1 with specific myoepithelial/mesenchymal markers varies
depending on the breast cancer subtype. Together, these data
indicate that as DCIS progresses to IDC, there are increasing
proportions of low-proliferative YB-1+E-cadherin cells with
invasive properties.
We next performed immunohistochemical staining for YB-1
and E-cadherin on tissue microarrays containing duplicate
cores of 143 in situ and IDC cases. This showed a statistically
significant inverse correlation between YB-1 and E-cadherin408 Cancer Cell 15, 402–415, May 5, 2009 ª2009 Elsevier Inc.expression levels in 65% of breast cancer specimens with
strong YB-1 staining (32% of total cases; p = 0.033; see
Figure S3C). Cases with strong E-cadherin and weak YB-1
expression consisted predominantly of DCIS or well-differenti-
ated IDC cases, while those lacking E-cadherin but strongly
positive for YB-1 tended to be high grade poorly-differentiated
IDC (for representative examples, see Figure S3D). We then
directly compared breast cancer-related survival in the strong
YB-1/weak E-cadherin subset to the weak YB-1/strong E-cad-
herin subset by Kaplan-Meier analyses. There was no significant
association between YB-1 expression alone and survival and
only a trend toward increased survival with high E-cadherin
expression alone (data not shown). However, compared to the
cases with weak YB-1/strong E-cadherin, strong YB-1/weak
E-cadherin expression correlated with significantly decreased
breast cancer survival (p = 0.0143; Figure S3E). These findings
provide compelling evidence that high YB-1 expression is asso-
ciated with loss of E-cadherin in invasive and, therefore, poten-
tially metastatic breast cancer cells and is indicative of poor
clinical outcome.
Cancer Cell
YB-1-Mediated Translational Control of EMTYB-1 Translationally Activates a Subset of mRNAs
Encoding EMT-Inducing Proteins
To better understand the mechanism underlying the EMT induc-
tion by YB-1, we performed microarray gene expression profiling
on MCF10AT cell lines. Since YB-1 is known to exert its regula-
tory effects at the transcriptional as well as translational levels,
we compared expression profiles of both total mRNAs and
mRNAs isolated from polysomal (Ps; translationally active) or
post-Ps (translationally inactive) fractions (Figure S4A).
Compared to MCF10AT-MSCV cells, 296 mRNAs were concor-
dantly downregulated in both total and Ps fractions from
MCF10AT-YB-1 cells, while 88 transcripts were upregulated
(Figure S5A). Consistent with the observed EMT in MCF10AT-
YB-1 cells, expression of an epithelial mRNA cluster (E-cadherin,
claudins 1, 4, and 7, desmoplakin, desmocollins 2 and 3, keratins
4, 15, 16, and 17, and integrins a6 and b6) was reduced in these
cells, while multiple mesenchymal-associated mRNAs (N-cad-
herin, decorin, vimentin, fibronectin, and integrin a5) were sig-
nificantly upregulated (Figures S5A and S5B and Table S1).
Consistent with their dedifferentiated phenotype, MCF10AT-
YB-1 cells also showed reduction of cell surface markers CD24
and CD82/KAI1 and elevation of CD10, CD44, and CD68.
Considering the predominantly cytosolic localization of YB-1
in our cell models, we hypothesized that some of the observed
transcriptional changes might be secondary to changes in
YB-1-mediated translational regulation of specific mRNA
subsets. To identify such mRNAs, we analyzed transcripts that
were equally expressed within total RNA populations of the
two cell lines, but were selectively decreased or increased in
Ps fractions from MCF10AT-YB-1 cells. Consistent with a cap-
dependent translational repressor function for YB-1, the majority
of transcripts (>80%) detected in Ps RNA preparations from
MCF10AT-YB-1 cells were reduced relative to MCF10AT-
MSCV cells. Among these were multiple cyclin mRNAs such as
cyclin B1, D1, and D3 (Figures S4B and S4C), further supporting
the direct involvement of YB-1 in their translational repression.
Surprisingly, however, we also identified a small subset of
transcripts that were selectively enriched in Ps fractions from
MCF10AT-YB-1 cells (Figure 6A). These included Snail1 and
other transcripts encoding well-known transcriptional inducers
of EMT, such as two members of the high-mobility group tran-
scription factor family, Lef-1 and TCF4, the zinc finger/homeodo-
main transcriptional repressor Zeb2/Sip1, and hypoxia-inducible
factor 1 a (HIF1a). The basic helix-loop-helix transcriptional
regulator and EMT-inducer Twist was upregulated at both tran-
scriptional and translational levels (Figure 6 and Table S1). There
was also significant representation of messages implicated in
early development and morphogenesis, as well as numerous
transcription factors with unknown functions. These included
two other Snail superfamily members, Snail3 and Scratch1,
and multiple members of zinc finger, basic helix-loop-helix,
homeobox (HOX), and high-mobility group transcription factor
families. Semiquantitative RT-PCR analysis using the corre-
sponding primers (Table S4) showed that, with a few exceptions,
the majority of these messages were indeed equally expressed
in total RNA populations from both MCF10AT-MSCV and
MCF10AT-YB-1 cell lines but selectively enriched in Ps RNA
fractions from MCF10AT-YB-1 cells (Figure 6B). A correspond-
ing increase in protein expression was confirmed by immuno-blotting (Figure 6C). In addition to Snail1 and Twist, we observed
elevated expression of Lef-1, Foxo3a, HoxC6, and HIF1a. Inter-
estingly, some of these proteins, including Foxo3a and HoxC6,
were translationally induced by YB-1 even in MCF10A-YB-1
cells, indicating that YB-1 may also translationally activate
certain messages in nontransformed cells. In summary, we
observed concordant translational activation of multiple EMT-
associated factors in YB-1-overexpressing breast epithelial cells
and their combined action is likely responsible for the switch
from an epithelial to mesenchymal gene expression program.
Elevated Levels of YB-1 Correlate with Translational
Induction of Snail1 and Snail1-Mediated Loss
of E-Cadherin in Multiple Cell Types
We next wished to confirm that YB-1 is required for translational
activation of the major inducers of EMT identified in our study.
We predominantly focused on Snail1 and Twist since their roles
in EMT and breast cancer invasiveness are well established
(Thiery and Sleeman, 2006). Snai1l transcripts were present in
MCF10AT cell lines and not in their normal MCF10A counterparts
and were translationally active predominantly in MCF10AT-YB-1
cells (i.e., present in Ps fractions and expressed at the protein
level; see Figures 6B and 6C and Figure S6A). Expression of
Twist was elevated in MCF10AT-YB-1 cells at both transcrip-
tional and translational levels (Figures 6B and 6C). This is in
contrast to the Snail1 homolog Snail2/Slug, whose expression
levels were not changed in any of the cell lines analyzed (Figures
6B and 6C). Similar results were obtained using the nontrans-
formed mouse mammary epithelial cell line EpH4 and its
H-Ras-transformed counterpart. In contrast to parental EpH4
cells, ectopic expression of YB-1 in EpH4-H-Ras cells led to
induction of Snail1, vimentin, and SMA, loss of E-cadherin
expression, and disruption of mammary acinar architecture
and polarity (Figures S1B and S1C). These results indicate that
YB-1 induces Snail1 protein expression and EMT-like changes
in Ras-transformed mammary epithelial cells of different origins
and are consistent with previous findings showing that onco-
genic H-Ras (G12V) activates the Snail1 promoter in a Ras-
ERK-dependent manner (Peinado et al., 2003). Similarly,
HoxC6 and Zeb2 expression levels were reduced in MCF10AT-
YB-1 cells by treatment with the MEK inhibitors UO126 or
PD98059 but not with wortmannin (Figure S6B). Interestingly,
Twist expression may require both Ras-ERK and PI3K-AKT
signaling as it was inhibited by wortmannin to an extent compa-
rable to that observed with MEK inhibitors. Therefore, it is likely
that two sequential steps are required for expression of Snail1
and certain other EMT-inducing proteins: (1) transcriptional
activation of the gene by elevated Ras-ERK signaling and (2)
YB-1-dependent translational activation of the corresponding
mRNA.
To further establish a link between YB-1, Snail1, and Twist
expression levels, we analyzed a panel of metastatic versus non-
metastatic human cancer cell lines. Similar to invasive breast
carcinoma cells (Figure 5C), endogenous levels of YB-1 were
elevated exclusively in metastatic cell lines and correlated with
the loss of E-cadherin and induction of Snail1, Twist, N-cadherin,
and vimentin (Figure 7A). Notably, knockdown of YB-1 in two
mesenchymal-like cell lines, MDA-MB-231 and MDA-MB-
435S, inhibited expression of Snail1 and Twist as well asCancer Cell 15, 402–415, May 5, 2009 ª2009 Elsevier Inc. 409
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YB-1-Mediated Translational Control of EMTFigure 6. YB-1 Translationally Activates a Subset of mRNAs Encoding EMT-Inducing Proteins
(A) Candidate mRNAs identified by microarray analysis as being translationally activated (enriched in Ps fractions) in MCF10AT-YB-1 cells relative to
MCF10AT-MSCV cells. Fold upregulation is measured as Ps/total RNA ratio.
(B) Levels of selected candidate mRNAs in total and Ps fractions from MCF10A and MCF10AT cell lines were examined by semiquantitative RT-PCR.
Endogenous GAPDH mRNA level was used as an internal control.
(C) Protein expression of selected candidate proteins was confirmed by immunoblotting. Actin was used as a loading control.N-cadherin, as shown by using several independent YB-1
siRNAs (Figure 7B and Figure S6C). While MDA-MB-231 is well
established as a metastatic breast cancer cell line, MDA-MB-
435 cells are now known to derive from a metastatic melanoma410 Cancer Cell 15, 402–415, May 5, 2009 ª2009 Elsevier Inc.(Rae et al., 2007), demonstrating potentially wider roles for YB-1
in epithelial malignancies. In agreement with a direct involvement
of YB-1 in regulating cyclin D1 expression, YB-1 knockdown led
to increased cyclin D1 levels (Figure 7B). Of further note,
Cancer Cell
YB-1-Mediated Translational Control of EMTFigure 7. Efficient Translation of Snail1 mRNA Requires Elevated Levels of YB-1
(A) Expression of YB-1, Snail, Twist, and their downstream targets in immortalized nontransformed mammary epithelial cells (HMT3522S), nonmetastatic breast
cancer cell lines (T47D, MCF7, HCC1937, and MDA-MB175), and metastatic breast cancer (MDA-MB-231, MDA-MB-436, and SUM1315MO2) and melanoma
(MDA-MB-435S) cell lines was examined by immunoblotting. Relative amounts of YB-1, Snail1, and Twist averaged from three independent experiments are
indicated at the bottom.
(B) MDA-MB-231 or MDA-MB-435S cells were transiently transfected with 25 nM of scrambled (CTRL) or YB-1 siRNAs. The expression of YB-1, Snail1, Twist,
and their downstream targets was examined by immunoblotting 4 days after transfection.
(C and D) MCF10AT-YB-1 cells were transiently transfected with 20 nM of scrambled (CTRL), YB-1, or SNAIL1 Smart siRNA pools. The expression levels of YB-1,
Snail1, and their downstream targets were examined 4 days later by immunoblotting (C) or immunofluorescence microscopy (D). Scale bars, 25 mm. Note that
some cell clusters remained positive for YB-1 and negative for E-cadherin, likely reflecting 30%–50% transfection efficiencies.
(E) Alignment of Snail1 50UTRs from different species. Asterisks indicate conserved nucleotides.
(F) Immunoblot of Snail1, Twist, and cyclin D1 expression in MCF10AT-YB-1 cells treated with 50 nM rapamycin ± cycloheximide (CHX; 20 mg/ml). 4E-BP1 phos-
phorylation pattern confirms blockade of the mTOR pathway by rapamycin.
(G) Analysis of the human Snail1 50UTR secondary structure using Vienna RNA secondary structure prediction tool (http://rna.tbi.univie.ac.at/cgi-bin/RNAfold.
cgi). The start AUG codon is shown in red and the conserved nucleotides are marked blue.
(H) Capped LucmRNA (40 ng;0.067 pmol) harboring 50UTRs of either b-globin orSnail1were incubated in rabbit reticulocyte lysates in the absence or presence
of increasing amounts of YB-1. After 60 min incubation at 30C, translation reactions were resolved by 10% SDS-PAGE and [35S]methionine-labeled translation
products were detected by autoradiography. Results of four independent experiments were quantified by phosphorimaging software and the data are presented
as mean ± SD.
(I) pcDNA3 plasmids encoding firefly Luc under control of the 50UTR of either b-globin or Snail1 were transiently transfected into MCF10AT-MSCV or MCF10AT-
YB-1 cells, along with a renilla Luc reporter (pRL) for normalization. Where indicated, cells were starved prior to transfection or starved and simultaneously treated
with 50 nM of rapamycin (see Supplemental Experimental Procedures). Luciferase activities were measured after 24 hr. The data are mean ± SD of three separate
transfections performed in duplicate.inhibition of Snail1, Twist, and N-cadherin paralleled downregu-
lation of YB-1 and was detected as early as day 4 after transfec-
tion, whereas reexpression of the epithelial markers E-cadherin
and ZO-1 was significantly delayed (Figure S6C), suggestingthat additional factors may be necessary for complete reversion
of the mesenchymal phenotype.
We next wished to test whether YB-1 is directly responsible for
the enhanced expression of Snail1 and loss of E-cadherin andCancer Cell 15, 402–415, May 5, 2009 ª2009 Elsevier Inc. 411
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MCF10AT-YB-1 cells resulted in virtually undetectable Snail1
protein levels, whereas Snail1 knockdown did not affect YB-1
expression (Figure 7C). As expected, MCF10AT-YB-1 cells
with reduced Snail1 levels regained expression of E-cadherin
and lost that of N-cadherin, vimentin, and SMA (Figures 7C
and 7D). However, in contrast to YB-1 knockdown cells in which
there was clear membrane localization of E-cadherin, in cells
treated with Snail1 siRNAs E-cadherin localization was diffuse,
with a significant portion remaining cytosolic (Figure 7D). Also,
in contrast to YB-1 knockdown (Figure 3B), MCF10AT-YB-1 cells
with Snail1 knockdown failed to re-form acinar structures when
grown in Matrigel (data not shown). Therefore, although Snail1
appears to be at least partially responsible for disrupted polarity
and loss of E-cadherin in MCF10AT-YB-1 cells, additional
EMT-inducing factors must be inactivated in these cells to fully
restore their epithelial phenotype. Candidates include Twist
and other factors identified in our studies and experiments are
underway to investigate these possibilities.
YB-1 Stimulates Translation of Snail1 mRNA
While Inhibiting Cap-Dependent Translation
We next investigated the mechanism of translational activation
of Snail1 mRNA in MCF10AT-YB-1 cells. The fact that Snail1
is translationally activated in the presence of the known cap-
dependent translational repressor YB-1 points to the possibility
of cap-independent translation initiation. This was further sup-
ported by the results showing that rapamycin, which is known
to inhibit cap-dependent but not cap-independent translation
(Beretta et al., 1996), did not affect Snail1 levels in MCF10AT-
YB-1 cells, while completely abolishing cyclin D1 expression
(Figure 7F, lanes 1–7). Maintenance of Snail1 expression in the
presence of rapamycin was not due to increased Snail1 protein
stability, as cotreatment of MCF10AT-YB-1 cells with the protein
synthesis inhibitor cycloheximide resulted in rapid disappear-
ance of Snail1 (Figure 7F, lanes 8–14). Thus, Snail1 expression
under these conditions is due to continuing eIF4E- and cap-inde-
pendent translation initiation. Similar patterns of Twist expres-
sion (Figure 7F) suggest a cap-independent translation initiation
mechanism as well.
To determine whether Snail1 mRNA harbors specific regula-
tory motifs in its 50UTR that are responsible for its cap-indepen-
dent translation initiation, the human Snail1 mRNA 50UTR was
compared to other species. With the notable exception of
Drosophila, Snail1 mRNA 50UTRs from primates, mouse, lizard,
chicken, and Xenopus are relatively short (70 nucleotides)
and contain several highly conserved G-C-enriched nucleotide
clusters (Figure 7E). Snail1 50UTRs from these different species
are predicted to form similar highly stable stem-loop structures
with conserved nucleotides mapping primarily to the stem
regions, whereas the 4- to10-nt-long loops exhibit a high degree
of variability (Figure 7G). Such evolutionary conservation and
complex secondary structure may be indicative of an internal
ribosome entry site (IRES), which is known to mediate cap-
independent translation initiation (Stoneley and Willis, 2004).
This possibility was further supported by in vitro translation
experiments. Using a reporter Luc mRNA linked to the 50UTR
of either Snail1 or control b-globin for in vitro translation experi-
ments, we found that in contrast to 50b-globin-Luc, translation412 Cancer Cell 15, 402–415, May 5, 2009 ª2009 Elsevier Inc.efficiency of 50Snail1-Luc mRNA was independent of the
presence or absence of a cap structure (data not shown) and
was substantially lower than that of 50b-globin-Luc mRNA
(Figure 7H). Furthermore, YB-1 inhibited cap-dependent transla-
tion of 50b-globin-Luc, while stimulating translation of 50Snail1-
Luc mRNA (Figure 7H). Further elevation of YB-1 above the
physiological threshold resulted in translational repression of
both mRNAs studied, consistent with the reported nonspecific
translation inhibitory activity of YB-1 (Evdokimova et al., 2001).
Transient transfection experiments revealed that despite similar
translational activities of both 50b-globin-Luc and 50Snail1-Luc
constructs in exponentially growing vector alone or YB-1-over-
expressing MCF10AT cell lines, translation of 50Snail1-Luc in
MCF10AT-YB-1 cells was substantially higher under conditions
of starvation or starvation combined with rapamycin treatment
(Figure 7I). These results suggest that the 50UTR of Snail1
mRNA potentially contains an IRES element that mediates
cap-independent translation initiation, especially under condi-
tions where cap-dependent translation is restricted by nutrient
deprivation. Given YB-1’s ability to inhibit cap-dependent trans-
lation and to stimulate IRES-driven translation initiation (Cobbold
et al., 2007; Evdokimova et al., 2006b), we thus propose that
YB-1 positively regulates Snail1 mRNA translation via an IRES-
dependent translation initiation mechanism.
DISCUSSION
This study presents a distinctive model of gene regulation during
metastatic progression, in which translational regulation by YB-1
is a restriction point controlling the coordinated repression of
genes associated with cellular proliferation and the epithelial
phenotype, while facilitating activation of a mesenchymal gene
expression program. Induction of the latter appears to be
a two-step mechanism involving Ras-ERK-dependent transcrip-
tion of Snail1 and other developmentally regulated genes and
YB-1-mediated translation of the corresponding messages into
protein products. In turn, these newly expressed pleiotropically
acting proteins are responsible for subsequent transcriptional
repression of E-cadherin and other epithelial genes and activa-
tion of mesenchymal genes (for a model, see Figure S7). Consis-
tent with its important role in triggering a mesenchymal-like
phenotype, YB-1 expression in human breast cancers and in
MCF10AT cells injected into mouse mammary fat is associated
with microinvasion and metastatic dissemination of low-prolifer-
ating mesenchymal-like cells.
Expression of YB-1 in normal breast epithelium and its cyto-
solic localization suggest an important role for YB-1 in restricting
cap-dependent translation of growth-related mRNAs. YB-1
upregulation observed in multiple human malignancies may
thus represent an adaptive cellular mechanism directed to over-
come uncontrolled proliferation. On the other hand, YB-1 was
reported to induce IRES-dependent translation of certain
mRNAs (Cobbold et al., 2007) and, in our study, was indispens-
able for translational activation of a subset of mRNAs whose
protein products are involved in morphogenesis and tumor
progression. Among them, we identified Snail1, Twist, Zeb2/
Sip1, HoxC6, Foxo3a, HIF1a, Lef-1, and others. Transcription
of many of the corresponding mRNAs occurs during normal early
embryonic development and is likely activated in carcinoma cells
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inhibition of Ras-ERK but not PI3K-AKT signaling in our experi-
mental system reduced the expression levels of Snail1, Twist,
HoxC6, and Zeb2 mRNAs. Translation of at least some of these
mRNAs, including HIF1a and Lef-1, was previously reported to
be driven by IRES elements that allow for their selective transla-
tion during hypoxia and starvation (Jimenez et al., 2005; Lang
et al., 2002; Stoneley et al., 2001). Our data indicates that the
Snail1 50UTR allows translation of a reporter mRNA under condi-
tions of starvation and inhibition of cap-dependent translation in
a YB-1-dependent manner (Figures 7F and 7I). Therefore, an
intriguing possibility is that YB-1 contributes to inhibition of
cap-dependent translation of growth-related mRNAs while
simultaneously activating IRES-dependent translation of the
aforementioned messages in hypoxic and nutrient-deprived
tumor areas, thereby promoting acquisition of a mesenchymal-
like migratory properties and facilitating tumor spread.
Although the link between YB-1 upregulation and tumor
aggressiveness is well established (Bergmann et al., 2005;
Janz et al., 2002), the precise mechanism has remained largely
unknown. Our findings suggest that YB-1 operates upstream
of key cellular pathways contributing to metastatic competence
and tumor dormancy. For instance, by enabling expression of
multiple embryonic transcription factors in carcinoma cells,
YB-1 activates an EMT program that is normally functional in
early embryogenesis. An important finding of this study is that
it is not a single factor but likely a complex network of transcrip-
tional regulators that is translationally controlled by YB-1. In
addition to well-established EMT inducers such as Snail1, Twist,
and Zeb2, which are known to mediate metastatic tumor
progression and tumor recurrence in breast cancer (Barrallo-
Gimeno and Nieto, 2005; Moody et al., 2005; Peinado et al.,
2007; Yang et al., 2006), we identified several other potential
EMT regulators whose activities may have equal importance in
these processes. Among these are homeodomain-containing
protein HoxC6 and c-Myc antagonist/growth inhibitor Mnt,
which are both involved in mammary morphogenesis (Garcia-
Gasca and Spyropoulos, 2000; Toyo-oka et al., 2006), and
a regulator of cell movement and polarity, PRICKLE1 (Katoh,
2005). Although the role of these proteins in EMT remains to be
proven, the majority function as transcriptional repressors and
inhibitors of cell growth. Given the coordinated switch in gene
expression profiles observed when MCF10AT cells overexpress
YB-1, it is likely that these YB-1-induced transcription factors act
in concert to inhibit growth-related and epithelial genes and to
activate mesenchymal genes, potentially leading to invasive
and metastatic behavior.
Upregulation by YB-1 of a large number of growth suppres-
sors, including Snail1 and Zeb2 themselves (Mejlvang et al.,
2007; Vega et al., 2004), is striking since tumorigenesis is typi-
cally associated with increased cell proliferation. It is tempting
to speculate that antiproliferative activity is a common feature
of EMT-promoting proteins and an integral part of the mesen-
chymal phenotype, allowing migrating embryonic or cancer cells
to reach their destinations before resuming growth. Subsequent
inactivation of this growth-suppressive program could be a very
inefficient process, as solitary disseminated tumor cells may be
detected in bone marrow and distant organs years before the
development of overt metastasis, remaining viable yet unableto reenter the cell cycle (Brackstone et al., 2007; Gupta and
Massague´, 2006). These slow-growing, nonapoptotic but highly
mobile tumor cells are likely to be insensitive to therapeutic inter-
ventions that primarily target proliferating cells. Their inability to
proliferate may also explain why mesenchymal-like cells are
rarely detected in human carcinomas. Interestingly, MCF10AT-
YB-1 cells appear to possess several stem cell properties,
including low proliferation rates, upregulation of the stem cell
markers p63, CD44, and CD10, and downregulation of CD24.
Further studies are necessary to determine whether YB-1
expression and upregulation of EMT inducers is correlated with
a stem cell phenotype, particularly in light of recent data sug-
gesting a link between stem cells and EMT in breast cancer
(Mani et al., 2008).
EXPERIMENTAL PROCEDURES
Cell Cultures and Xenografts
MCF10A and MCF10AT (MCF10AT1k.cl2) cell lines were obtained from
Dr. Fred Miller and cultured as previously described (Debnath et al., 2003).
SUM1315MO2 was obtained from Asterand. The other breast cancer cell lines,
HeLa, and PC3 cells were purchased from American Type Culture Collection.
The biological characteristics and culture conditions for each cell line are
summarized in Table S2. Stable polyclonal cell lines expressing vector alone
or HA-tagged YB-1 were generated by retroviral infection as described previ-
ously (Sorokin et al., 2005). For in vivo bioluminescent studies, cells were
engineered to express mCherry, selected by FACS sorting, tested for expres-
sion of characteristic markers, and orthotopically transplanted (53 105 in 50 ml
PBS) into the mammary glands of NOD/SCID mice. Three months after surgery
different tissues were formalin fixed (for immunohistochemistry) or flash frozen
(for RNA isolation and immunoblotting). Animal experiments were conducted
following protocols approved by the University of British Columbia’s Animal
Care Committee.
Clinical Samples
A tissue microarray consisting of 175 cases of in situ and invasive breast
cancer in duplicate was constructed from formalin-fixed paraffin-embedded
tissues sent to the Vancouver General Hospital. Clinical follow-up data for
20 years was available for each case. This study was approved by the Clinical
Research Ethics Board of the University of British Columbia (HO6-70105), and
all patient identifiers were removed from the samples prior to analysis.
Cell Fractionation, RNA Isolation, and Microarray Analysis
Total cell extracts were prepared from subconfluent cells using Nonidet P-40
lysis buffer (20 mM HEPES-KOH [pH 7.6], 100 mM KCl, 5 mM MgCl2, 2 mM
dithiothreitol, 0.25% Nonidet P-40, 2 mg/ml leupeptin, 2 mg/ml pepstatin, and
10 mg/ml cycloheximide). Cell fractionation and purification of Ps and post-
Ps fractions were performed as previously described (Evdokimova et al.,
2006b; Sorokin et al., 2005). Five micrograms of each RNA sample was
used for microarray probe synthesis and hybridization as described in the
Affymetrix GeneChip manual. For each fraction, two independently isolated
RNA samples were hybridized to Affymetrix GeneChip Human Exon 1.0 ST
(HuEx 1.0) arrays. Gene-level signal estimates were derived from the CEL files
by RMA-sketch normalization (core probe sets only) as previously described
(Abdueva et al., 2007; Davicioni et al., 2006), and a variance filter was applied
to eliminate genes whose standard deviation from the mean was <10 expres-
sion units of a normalized data range, leaving 7368 summarized transcripts.
Differentially expressed transcripts between MCF10AT-YB1 and MCF10AT-
MSCV cells in each cellular fraction were selected based on a mean fold
difference of 1.5 and the associated t test, with a p value%0.05. Expression
analysis was performed using the Genetrix software package (Epicenter Soft-
ware).
siRNA Transfections
For transient knockdown of YB-1 or Snail1, cells were transfected at 30%
confluence in 6 well plates with a Smart siRNA pool (Dharmacon)Cancer Cell 15, 402–415, May 5, 2009 ª2009 Elsevier Inc. 413
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YB-1-Mediated Translational Control of EMTcomplementary to four different regions of the corresponding mRNA or with
single YB-1 siRNAs (#1: UGACACCAAGGAAGAUGUAUU; #2: GUGAGAGUG
GGGAAAAGAAUU) using the SilentFect (Bio-Rad) reagent according to the
manufacturer’s instructions. Concentrations of siRNAs were optimized for
each cell line and are indicated in the figure legends.
Immunoblotting, Immunofluorescence, and Immunohistochemistry
Immunoblotting and immunofluorescence were performed as described
previously (Sorokin et al., 2005). For origin, description, and dilutions of all
antibodies used in this study see Table S3. Immunofluorescence and immuno-
histochemistry on formalin-fixed, paraffin-embedded tissues was performed
after deparaffinization and antigen retrieval. Immunohistochemistry staining
was performed using the alkaline-phosphatase-labeled streptavidin-biotin
ABC kit and hematoxylin was used as a counterstain (Vector Labs). Images
were acquired with an Axioplan2 fluorescence microscope (Zeiss) or confocal
Nikon Eclipse TE2000-E microscope, converted to TIFF format, and arranged
using Photoshop 7.0.
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